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Abstract
Background: Community-acquired pneumonia (CAP) is a frequent complication of chronic obstructive pulmonary disease
(COPD), but previous studies are often contradictory.
Objectives: We aimed to ascertain the characteristics and outcomes of CAP in patients with COPD as well as to determine
the risk factors for mortality and Pseudomonas aeruginosa pneumonia in COPD patients with CAP. We also describe the
etiology and outcomes of CAP in COPD patients receiving chronic oxygen therapy at home and those receiving inhaled
steroids.
Methods: An observational analysis of a prospective cohort of hospitalized adults with CAP (1995–2011) was performed.
Results: We documented 4121 CAP episodes, of which 983 (23.9%) occurred in patients with COPD; the median FEV1 value
was 50%, and 57.8% were classified as stage III or IV in the GOLD classification. Fifty-eight per cent of patients were receiving
inhaled steroids, and 14.6% chronic oxygen therapy at home. Patients with COPD presented specific clinical features. S.
pneumoniae was the leading causative organism overall, but P. aeruginosa was more frequent in COPD (3.4 vs. 0.5%; p,
0.001). Independent risk factors for case-fatality rate in patients with COPD were multilobar pneumonia, P. aeruginosa
pneumonia, and high-risk PSI classes. Prior pneumococcal vaccination was found to be protective. FEV1 was an independent
risk factor for P. aeruginosa pneumonia.
Conclusions: CAP in patients with COPD presents specific characteristics and risk factors for mortality. Prior pneumococcal
vaccine has a beneficial effect on outcomes. P. aeruginosa pneumonia is associated with low FEV1 values and poor
prognosis.
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Introduction
Chronic obstructive pulmonary disease (COPD) is one of the
leading causes of morbidity and mortality worldwide. Recent
projections predict that by 2030 it will be the fourth main cause of
death and the seventh cause of the global burden of disease,
presenting a significant increase compared to data from 2002 [1].
Its prevalence is around 1% across all age groups, increasing to
10% in patients aged 40 years and over. Around 2.5 million people
die of the disease each year [2–5].
Community-acquired pneumonia (CAP) is one of the most
frequent infections requiring hospitalization in developed countries
[6]. In COPD patients, CAP is one of the most common infections
[7]. Patients with COPD have structural disruptions in the lung
parenchyma [8] and frequently receive antibiotic and oral or
inhaled steroid treatment. Moreover, COPD is characterized by a
chronic inflammation of the airways [9] and it has been suggested
that patients may present changes in their local and systemic
immune response [10]. For all these reasons, the presentation of
CAP in patients with COPD may differ from that of patients
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without the condition. Prior studies have evaluated the character-
istics of patients with COPD and CAP [11–20], but the results are
contradictory: many issues such as factors related to mortality, risk
factors for Pseudomonas aeruginosa pneumonia or etiology, and
outcomes in patients with chronic oxygen therapy at home or
using inhaled steroids are still unclear and in need of clarification.
The aims of this study were: 1) to determine the epidemiology,
clinical features and outcomes of patients with COPD in a large
prospective cohort of non-severely immunosuppressed hospitalized
adults with pneumonia; 2) to analyse risk factors for mortality in
patients with COPD and CAP; 3) to assess clinical characteristics,
risk factors for and outcomes of P. aeruginosa pneumonia in
patients with COPD, and 4) to describe the etiology and outcomes
in patients with COPD receiving chronic oxygen therapy at home
and in those receiving inhaled steroids treatment.
Materials and Methods
Ethics statement
The study was approved by the Ethical Committee of Hospital
Universitari de Bellvitge. To protect personal privacy, identifying
information of each patient in the electronic database was
encrypted.
Setting, patients and study design
This observational study was conducted at an 800-bed
university hospital for adults in Barcelona, Spain. All non-severely
immunosuppressed adult patients admitted to the hospital with
pneumonia through the emergency department from February
1995 through October 2011 were prospectively recruited and
followed up. Patients with neutropenia, solid organ transplanta-
tion, chemotherapy, acquired immunodeficiency syndrome or
chronic corticosteroid therapy ($20 mg prednisone/day or
equivalent for at least two previous months) at admission were
excluded.
Clinical assessment and antibiotic therapy
Patients were seen daily during their hospital stay by one or
more of the investigators, who recorded clinical data in a
computer-assisted protocol. Data were collected on demographic
characteristics, comorbidities, causative organisms, antibiotic
susceptibilities, biochemical analysis, empirical antibiotic therapy,
and outcomes.
At the initial visit, before starting empirical antibiotic therapy,
patients underwent a complete clinical history and physical
examination. Basic chemistry and hematology tests, arterial blood
gas determinations and chest radiography were performed. Two
sets of blood samples were obtained and cultured and, when
available, a sputum sample was evaluated by Gram staining and
culture. Urinary antigen detection tests for Streptococcus pneumo-
niae and Legionella pneumophila were performed if indicated by
the attending physician.
Forced expiratory volume in the first second (FEV1), chronic
oxygen therapy at home and inhaled therapy information were
recorded after reviewing the spirometry and hospital databases.
To stratify patients into pneumonia risk classes, the pneumonia
severity index (PSI) was used [21].
Antibiotic therapy was initiated in the emergency department in
accordance with the hospital guidelines, which recommend the
administration of a b-lactam (ceftriaxone sodium or amoxicillin/
clavulanate potassium) with or without levofloxacin. Combination
therapy was recommended for patients with clinical suspicion of a
Legionella species or an atypical pathogen, or in the absence of a
demonstrative finding on sputum Gram stain results. Levofloxacin
monotherapy was recommended for patients with a positive urine
antigen test for L. pneumophila serogroup 1, as described
elsewhere. Combined amoxicillin/clavulanate was recommended
for patients with clinical suspicion of aspiration pneumonia.
Definitions
Pneumonia was defined as the presence of an infiltrate on a
chest radiography plus an acute illness associated with one or more
of the following signs and symptoms: new cough with or without
sputum production, pleuritic chest pain, dyspnea, fever or
hypothermia, altered breath sounds on auscultation or leukocytosis
[6].
COPD was defined as the coexistence of chronic and
progressive symptoms such as dyspnea, cough and sputum and
airflow obstruction diagnosed by spirometry (basal forced spirom-
etry showing FEV1#70% of its reference value and b2-agonist
reversibility of predicted FEV1 of ,15% and/or 200 ml. with
FEV1/FVC ,70%). Patients were stratified into four stages
according to the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) criteria [22]. GOLD stage I or mild COPD was
defined as FEV1$80% predicted, GOLD stage II or moderate
COPD as 50%# FEV1,80% predicted, GOLD stage III or
severe COPD as 30% #FEV1,50% predicted and GOLD stage
IV or very severe COPD as FEV1,30% predicted or FEV1,50%
predicted with chronic respiratory failure.
Patients who had smoked more than 10 cigarettes per day for at
least one year preceding the study were classified as current
smokers. Alcohol abuse was considered if alcohol intake was .3
standard drinks per day. Pre-hospital antibiotic treatment was
defined as the oral intake of antibiotic drugs .24 hours prior to
hospitalization for the same episode of acute disease. Patients were
classified as receiving antibiotics if they self-reported prescription
of any of these medications or by reviewing the prescriptions from
their General Practitioner at the SAP Healthcare Database of the
Catalan Health Service (Institut Català de la Salut). Prior
antibiotic treatment was defined as the intake of antibiotic drugs
.3 months prior to hospitalization.
Vaccination status was assessed from interviews with the
patients or their relatives and from reviews of hospital and
personal health records (vaccination card). Patients were consid-
ered to be pneumococcal-vaccinated if the 23-valent polysaccha-
ride pneumococcal vaccine had been administered in the five years
before admission, and influenza-vaccinated if seasonal influenza
vaccine had been administered during the year prior to admission.
Patients were considered to be on chronic oral steroids if they
received more than 5 mg prednisone/day or equivalent for at least
the two previous months. Respiratory failure was defined as a
PaO2/FiO2 ratio less than 300. The diagnosis of septic shock was
based on a systolic blood pressure of less than 90 mmHg, and
diagnosis of peripheral hypoperfusion on the need for vasopres-
sors. A comorbid condition was defined as the presence of one or
more disorders in addition to COPD. Initial inappropriate therapy
was defined as the absence of antimicrobial agents directed at a
specific type of organism or administration of an antibiotic to
which the organism was resistant, according to susceptibility test
criteria for lower respiratory tract pathogens.
Complications were defined as any untoward circumstances
occurring during hospitalization, with the exception of side effects
of medication. In-hospital cardiac events included acute coronary
syndromes, arrhythmias and decompensated heart failure. Time to
clinical stability was defined as previously described by Halm et al
[23]. Early case-fatality rate was defined as death due to any cause
,48 h after hospitalization. Overall case-fatality rate was defined
as death due to any cause ,30 days after hospitalization.
Pneumonia in Patients with Chronic Obstructive Pulmonary Disease
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Microbiological studies and etiologic diagnosis
Pathogens in blood, normally sterile fluids, sputum, and other
samples were investigated using standard microbiological proce-
dures. Sputum specimens were usually collected under the
supervision of a registrar or nurse before antibiotic therapy was
begun. Specimens were sent to the laboratory and processed
immediately. No special procedures were performed for sputum
samples if they could not be obtained spontaneously. A Gram stain
was performed on a purulent portion of each sputum specimen
and examined by trained personnel. The slides were evaluated for
quality under low power (610). Salivary contamination was
defined by detecting squamous epithelial cells, and purulence was
determined by the presence of polymorphonuclear cells. Sputum
samples were considered of good quality if they had ,10
squamous cells and .25 leukocytes per low-power field. Other-
wise, the sputum sample was considered contaminated by saliva
and rejected. Good-quality specimens were then screened for a
predominant bacterial morphological type at oil immersion field
(6100). A predominant morphotype was defined as the presence
of a single morphotype that accounted for .75% of the organisms
seen. Sputum cultures were processed immediately in blood agar,
chocolate agar, and MacConkey agar media. Isolation of
Legionella pneumophila was also attempted by use of buffered
charcoal-yeast extract medium in selected cases.
The Streptococcus pneumoniae antigen in urine was detected by
using a rapid immunochromatographic assay (NOW Assay; Binax
Inc, Portland, Maine). Legionella pneumophila serogroup 1
antigen in urine was detected by an immunochromatographic
method (NOW Legionella Urinary Antigen Test; Binax Inc) or
enzyme-linked immunosorbent assay (ELISA-Bartels, Bartels,
Trinity Biotech, Wicklow, Ireland). Standard serologic methods
were used to determine antibodies against atypical agents (on
admission and 3–4 weeks thereafter). Antimicrobial susceptibility
was tested by the microdilution method, following the Clinical
Laboratory Standard Institute methods and criteria. Presumptive
aspiration pneumonia was diagnosed on a clinical and radiological
basis in patients who had risk factors such us compromised
consciousness, altered gag reflex, dysphagia, severe periodontal
disease, putrid sputum, and radiographic evidence of involment of
a dependent pulmonary segment or necrotizing pneumonia.
Statistical analysis
Categorical variables were described using counts and percent-
ages from available data. Continuous variables were expressed as
the mean and standard deviation (SD) or median and interquartile
range (IQR) for abnormally distributed data (Kolmogorov-
Smirnov test).
To detect differences we used the chi-square test or Fisher exact
test for categorical variables and t test or Mann-Whitney test for
continuous variables, when appropriate. A multivariate analysis
was carried out to determine independent risk factors for mortality
in patients with COPD and in those with both COPD and
Pseudomonas aeruginosa pneumonia. Significant variables detect-
ed in the univariate analysis and considered clinically important
were entered into the multivariate analysis. The relative risks were
expressed as odds ratios (OR) and 95% confidence intervals (CI).
The goodness-of-fit of the model was evaluated by the Hosmer-
Lemeshow test.
The results were analyzed using SPSS, version 15.0 (SPSS Inc,
Chicago, Illinois). A P-value of ,0.05 was considered statistically
significant. All reported P-values are two-tailed.
Results
Patient characteristics
During the study period, we documented 4121 CAP episodes, of
which 983 (23.9%) cases occurred in patients with COPD; the
median FEV1 value was 50% and 57.8% of these patients were
classified into stages III and IV of the GOLD classification. Fifty-
eight per cent of patients were receiving inhaled steroids and
14.6% chronic oxygen therapy at home.
Table 1 shows the demographic, clinical and laboratory
findings of patients with and without COPD. Patients with COPD
were older, more often male, current and ex-smokers and heavy
alcohol consumers. They were also more likely to have other
chronic comorbid conditions, especially chronic heart diseases and
neoplastic diseases, but less likely to have dementia. They had
received oral corticoids and previous antibiotics and had been
vaccinated against pneumococcus and influenza more often than
patients without COPD. Patients with COPD were also more
frequently classified as high-risk PSI.
Regarding clinical features, patients with COPD were more
likely to have cough, expectoration, purulent sputum, dyspnea,
tachypnea, and respiratory failure at admission. Conversely, fever,
diarrhea, headache, arthromyalgias, multilobar infiltrates, pleural
effusion, empyema and bacteremia were less common. Moreover,
patients with COPD were admitted to the hospital with fewer days
of clinical symptoms than those without the condition.
Causative organisms
Table 2 shows the distribution of causative organisms in the
two groups. Streptococcus pneumoniae was the most frequent
causative organism in patients from both groups. Haemophilus
influenzae and Gram-negative bacilli, especially Pseudomonas
aeruginosa, were more frequent in patients with COPD, while
Legionella pneumophila, atypical agents and aspirative pneumonia
were less common. Excluding ICU patients, PA was the cause of
pneumonia in 42 of 3727 patients (1.1%), 3.1% in COPD patients
and 0.5% in non-COPD patients (p,0.001). In patients admitted
in ICU, PA was the cause of pneumonia in 7 of 381 patients
(1.8%), 7.1% in COPD patients and 0.6% in non-COPD patients
(p,0.001).
Bacteremia occurred less often in patients with COPD than in
those without (9.1% vs. 13.3%; p= 0.001), as did pneumococcal
bacteremia. However, bacteremia caused by Pseudomonas
aeruginosa was more common.
Clinical outcomes
The susceptibility test for pathogen isolates indicated that most
patients had received adequate initial empirical antibiotic therapy
(Table 3). Patients with COPD had more ischemic cardiac
events, and CAP was more frequently recurrent.
Patients with COPD had a longer intravenous therapy and
length of hospital stay, although time to clinical stability was
similar in the two groups. No differences in early and overall case-
fatality rate were found between the groups. The overall case-
fatality rate in patients hospitalized in conventional wards was
5.5% in COPD patients and 5.6% in non-COPD patients
(p = 0.917). Analyzing only ICU patients, overall case-fatality rate
was 25.7%, 21 of 70 (30%) in COPD patients and 77 of 311
(24.8%) in non-COPD patients (p = 0.330).
Risk factors for case-fatality rates among patients with
COPD
Table 4 compares the demographic and clinical features of
patients with COPD who died and in those who survived. Patients
Pneumonia in Patients with Chronic Obstructive Pulmonary Disease
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Table 1. Characteristics of pneumonia by study group.
Variable
Patients with COPD [n = 983],
n (%)
Patients without COPD [n = 3138],
n (%) p value
Demographic data
Age, median (IQR), years 74 (67–80) 67 (52–78) ,0.001
.65 years old 785 (79.9) 1730 (55.2) ,0.001
Male sex 890 (90.5) 1912 (61) ,0.001
Current smoker 252 (25.8) 827 (26.6) ,0.001
Ex-smoker 535 (54.8) 744 (23.9)
Alcohol abuse 195 (20) 491 (15.8) 0.002
Influenza vaccine (season) 627 (71.4) 1199 (42.6) ,0.001
Pneumococcal vaccine, 5 years 226 (26.8) 381 (13.9) ,0.001
Comorbid conditions
Diabetes mellitus 216 (22) 639 (20.4) 0.280
Chronic heart disease 265 (27) 688 (21.9) 0.001
Neoplastic disease 112 (11.4) 255 (8.1) 0.003
Chronic renal disease 67 (6.8) 219 (7) 0.943
Chronic liver disease 63 (6.4) 200 (6.4) 1
Cerebrovascular disease 69 (7) 243 (7.7) 0.490
Cognitive deficit (dementia) 38 (3.9) 174 (5.5) 0.038
Statin use1 89 (25.8) 220 (20.9) 0.062
Chronic oral steroids 102 (10.4) 159 (5.1) ,0.001
Pre-hospital antibiotics 191 (19.1) 729 (23.9) 0.002
Prior antibiotic treatment 227 (23.1) 443 (14.1) ,0.001
Prior hospitalization (90 days)2 91 (12.3) 129 (5.5) ,0.001
Criteria of health-care associated pneumonia3 194 (26.2) 461 (19.7) ,0.001
Clinical features at presentation
Fever ($38.0uC) 437 (45) 1645 (52.9) ,0.001
Acute onset of disease 446 (45.5) 1385 (44.3) 0.532
Days of clinical symptoms at admission (IQR) 3 (1–5) 4 (2–6) ,0.001
Cough 859 (87.6) 2592 (83.2) 0.001
Expectoration 734 (74.8) 1812 (58) ,0.001
Purulent sputum 550 (63.7) 1354 (54.9) ,0.001
Dyspnea 765 (78) 1794 (57.4) ,0.001
Tachypnea ($30 breaths?min21) 429 (48.5) 1229 (43.3) 0.006
Pleuritic chest pain 419 (42.7) 1276 (40.9) 0.334
Impaired consciousness 135 (13.8) 466 (14.9) 0.407
Septic shock 67 (6.8) 238 (7.6) 0.443
Diarrhea, vomiting 85 (8.7) 519 (16.6) ,0.001
Headache 96 (9.8) 575 (18.4) ,0.001
Arthromyalgias 139 (14.2) 693 (22.2) ,0.001
Laboratory and radiographic findings at presentation
Respiratory failure (PaO2/FiO2,300 or PaO2,60 mmHg) 624 (76.2) 1563 (66.1) ,0.001
Multilobar pneumonia 255 (26) 1095 (75.3) ,0.001
Pleural effusion 134 (13.7) 558 (17.9) 0.002
Empyema 21 (2.1) 150 (4.8) ,0.001
Bacteremia 86 (9.1) 407 (13.3) 0.001
High-risk PSI classes4 720 (73.5) 1691 (54.1) ,0.001
COPD, chronic obstructive pulmonary disease; IQR, interquartile range; PSI, pneumonia severity index.
1Data available only for 1396 patients. 2Data available from January 2001, only for 3084 patients; 3Data available from January 2001, only for 3084 patients 4Patients
were stratified into the following risk classes according to the PSI score: low risk (#90 points, classes I, II, and III) and high risk (.90 points, classes IV and V).
doi:10.1371/journal.pone.0105854.t001
Pneumonia in Patients with Chronic Obstructive Pulmonary Disease
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e105854
who died were older and more often presented use of chronic oral
steroids, chronic renal disease, dementia, multilobar pneumonia,
bacteremia and septic shock at hospital admission. They were also
more likely to be classified into high-risk PSI classes, more
commonly received inappropriate empirical treatment, and more
frequently required intensive care unit (ICU) admission and
mechanical ventilation. Pneumonia due to Gram-negative bacilli
and aspiration pneumonia were significantly more common in
these patients, as were cardiac, metabolic, acute renal complica-
tions and nosocomial infections.
The results of the multivariate logistic regression analysis for
factors potentially associated with overall case-fatality rates in
patients with COPD are summarized in Table 5. After adjust-
ment, multilobar pneumonia, Pseudomonas aeruginosa pneumo-
nia, and high-risk PSI classes were found to be independent risk
factors for case-fatality rates. Conversely, pneumococcal vaccine
had a protective effect. The goodness-of-fit of the model was
0.908.
Risk factors for Pseudomonas aeruginosa pneumonia in
patients with COPD
We compared the characteristics of patients with COPD caused
by Pseudomonas aeruginosa pneumonia and those with pneumo-
nia caused by another pathogen (Table 6). Chronic liver disease
and treatment with chronic oral steroids were more common in
COPD patients with Pseudomonas aeruginosa pneumonia. These
patients were also more likely to be classified as GOLD stages III
and IV (50% versus 28.8%; p= 0.048), and to have received
chronic oxygen therapy at home (30.8% versus 14%; p= 0.018),
inhaled anticholinergics (80% versus 60.5%; p= 0.050) and long-
acting beta-agonists (72% versus 51.1%; p= 0.040). Median (IQR)
of FEV1 values was 40% (30–49) in patients with Pseudomonas
aeruginosa pneumonia and 49% (36–72) in the others. No
significant differences in PSI class were found between groups
(63.6% versus 73.8%). Patients with Pseudomonas aeruginosa
pneumonia more frequently received inappropriate empiric
antibiotic therapy (42.4% versus 3.3%; p,0.001). Patients with
COPD and P.aeruginosa pneumonia who received inappropriate
Table 2. Etiology of pneumonia by study group.
Variable Patients with COPD [n = 983], n (%) Patients without COPD [n = 3138], n (%) p value
Streptococcus pneumoniae 359 (36.5) 1047 (33.4) 0.069
Pneumococcal bacteremia 65 (6.9) 345 (11.3) ,0.001
Haemophilus influenzae 97 (9.9) 117 (3.7) ,0.001
Aspiration pneumonia 49 (5) 248 (7.9) 0.002
Legionella pneumophila 21 (2.1) 204 (6.5) ,0.001
Gram-negative bacilli 40 (4.1) 37 (1.2) ,0.001
Pseudomonas aeruginosa 33 (3.4) 16 (0.5) ,0.001
Pseudomonas aeruginosa bacteremia 10 (1.1) 4 (0.1) ,0.001
Atypical agents 15 (1.8) 152 (4.8) ,0.001
Others 29 (3) 178 (5.7) 0.001
No pathogen identified 412 (41.9) 1257 (40.1) 0.318
COPD, chronic obstructive pulmonary disease; 72 (7.3%) patients with COPD and 118 (3.7%) patients without COPD had more than one cause of community-acquired
pneumonia.
doi:10.1371/journal.pone.0105854.t002
Table 3. Antibiotic therapy and outcomes of pneumonia by study group.
Variable Patients with COPD [n = 983], n (%) Patients without COPD [n = 3138], n (%) p value
Inappropriate empiric antibiotic therapy 45 (7.8) 123 (6.9) 0.339
In-hospital complications 274 (27.9) 969 (31) 0.073
Cardiac complications 73 (7.4) 262 (8.4) 0.385
Ischemic cardiac complications 13 (1.3) 18 (0.6) 0.018
Recurrent CAP 40 (4.6) 61 (2.1) ,0.001
ICU admission 70 (7.1) 311 (9.9) 0.08
Need for mechanical ventilation 44 (4.5) 182 (5.9) 0.127
Length of intravenous therapy, median (IQR), days 4 (2–7) 4 (3–7) 0.041
Time to clinical stability, median (IQR), days 4 (2–8) 4 (2–7.25) 0.956
Length of hospital stay, median (IQR), days 8 (6–13) 8 (6–12) 0.004
Early case-fatality rate, #48 hours 14 (1.4) 75 (2.4) 0.069
Overall case-fatality rate 72 (7.3) 241 (7.7) 0.783
CAP: Community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; ICU: Intensive care unit; IQR, interquartile range.
doi:10.1371/journal.pone.0105854.t003
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empiric therapy were commonly classified as GOLD stage IV
(57%) and frequently received inhaled steroids (70%). Only one
patient was taking chronic oral steroids treatment. Early (15.2%
versus 0.9%; p,0.005) and overall (39.4% versus 6.2%; p,0.001)
case-fatality rates were higher.
After adjustment for chronic oral steroids, chronic liver disease,
GOLD stages III or IV, chronic oxygen therapy at home, inhaled
Table 4. Factors associated with mortality in patients with COPD and pneumonia: univariate analysis.
Variable Patients with COPD who died [n = 72], n (%) Patients with COPD and alive [n = 911], n (%) p value
Demographic data
Age, median (IQR), years 80 (73–85) 74 (66–80) ,0.001
.65 years old 65 (91.5) 719 (79) 0.011
Male sex 64 (88.9) 825 (90.7) 0.621
Current smoker 15 (21.4) 236 (26) 0.477
Influenza vaccine (season) 35 (64.8) 592 (71.8) 0.268
Pneumococcal vaccine, 5 years1 8 (15.4) 218 (27.6) 0.054
Chronic oral steroids 16 (22.9) 86 (9.5) ,0.001
Statin use 4 (17.4) 85 (26.4) 0.340
COPD data
COPD stages III or IV 8 (42.1) 158 (29) 0.220
Chronic oxygen therapy 4 (10.5) 104 (14.9) 0.462
Inhaled steroids 21 (56.8) 401 (58.3) 0.854
FEV1, median (IQR), % 41 (31.5–57.5) 49 (36–62) 0.279
Comorbid conditions
Diabetes mellitus 14 (19.4) 202 (22.2) 0.587
Chronic heart disease 25 (34.7) 239 (26.3) 0.119
Neoplastic disease 7 (9.7) 105 (11.5) 0.641
Chronic renal disease 12 (16.7) 55 (6) 0.001
Dementia 8 (11) 30 (3.3) 0.001
Clinical features at presentation
Septic shock 14 (19.4) 53 (5.8) ,0.001
Multilobar pneumonia 32 (45.1) 223 (24.6) ,0.001
Bacteremia 14 (20.6) 71 (8.1) 0.001
High-risk PSI classes n (%)2 69 (95.8) 650 (71.7) ,0.001
Etiology
Streptococcus pneumoniae 21 (29.2) 337 (37) 0.182
Legionella pneumophila 1 (1.4) 20 (2.2) 0.648
Haemophilus influenzae 7 (9.7) 90 (9.9) 0.963
Aspiration pneumonia 7 (9.7) 42 (4.6) 0.055
Gram-negative bacilli 14 (19.4) 24 (2.6) ,0.001
Pseudomonas aeruginosa 13 (18.1) 20 (2.2) ,0.001
Atypical agents 2 (2.8) 16 (1.8) 0.535
Other organisms 2 (2.8) 27 (3) 0.927
Antibiotic therapy and outcomes
Inappropriate empirical treatment 10 (13.9) 33 (3.6) 0.01
Mechanical ventilation 17 (23.9) 26 (2.9) ,0.001
ICU admission 21 (29.6) 48 (5.3) ,0.001
Cardiac complications 18 (25.4) 55 (6) ,0.001
Acute renal complications 15 (21.1) 20 (2.2) ,0.001
Metabolic complications 7 (9.9) 21 (2.3) ,0.001
Nosocomial infection 4 (5.6) 16 (1.8) 0.026
DM, diabetes mellitus; FEV1: Forced expiratory volume in the first second; ICU: Intensive care unit; IQR, interquartile range; PSI, pneumonia severity index.
1Data available only for 52 patients and 790 patients respectively; 2Patients were stratified into the following risk classes according to the PSI score: low risk (#90 points,
classes I, II, and III) and high risk (.90 points, classes IV and V).
doi:10.1371/journal.pone.0105854.t004
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anticholinergics and inhaled long-acting beta-agonists, only the
FEV1 value was found to be an independent risk factor for
Pseudomonas aeruginosa pneumonia (OR 0.166, IC 95% 0.032–
0.863, p = 0.028).
Etiology and outcomes of patients with COPD who
received chronic oxygen therapy at home and those with
inhaled steroids
In a further analysis, etiology and outcomes of patients with
COPD with and without chronic oxygen therapy at home were
compared. Although S. pneumoniae was the most common
causative organism in both groups (37% and 39.4% respectively),
Pseudomonas aeruginosa was more frequent in patients with
chronic oxygen therapy at home (7.4% versus 2.9%; p= 0.018)
while aspirative pneumonia was less common (0% versus 4.4%;
p= 0.026). No differences in early and overall case-fatality rates
were found.
In the last analysis, we compared etiology and outcomes of
patients with COPD who received inhaled steroids with those who
did not. Pneumococcal pneumonia was the most common etiology
in both groups (36.7% and 42.2% respectively). No differences in
etiologies and early and overall case-fatality rates were found
between groups.
Discussion
This prospective study of a large cohort of patients offers a
detailed evaluation of characteristics, etiology, and outcomes of
pneumonia in patients with COPD. The main findings were that:
1) patients with and without COPD had different clinical features
at admission; 2) although S. pneumoniae was the most frequent
causative organism, P. aeruginosa pneumonia and P. aeruginosa
bacteremia were more frequent in patients with COPD; 3)
mortality rates were similar in patients with and without COPD; 4)
independent risk factors for mortality in patients with COPD were
multilobar pneumonia, P. aeruginosa pneumonia, and high-risk
PSI classes; 5) pneumococcal vaccination was associated with
better outcomes; 6) the only independent risk factor for P.
aeruginosa pneumonia in patients with COPD was the FEV1
value; 7) no differences in mortality were found between patients
with COPD who were receiving chronic oxygen therapy at home
and those who were not; and 8) there were no differences in either
etiology or outcomes between patients with COPD who were
receiving inhaled steroids and those who were not.
We found COPD to be a frequent comorbid condition in
patients with CAP (23.9%). These results are in agreement with
those of other researchers who reported rates between 15% and
42%, depending on the population studied [12–14,16–18,20,24].
Comparing the clinical picture of CAP at admission in patients
with and without COPD, patients with COPD presented more
often with cough, sputum and respiratory failure, as expected.
Interestingly, fever, extensive radiographic infiltrates or pleural
effusion/empyema were less frequent. This is consistent with data
from Sellares and coworkers [19], who also documented a
decreased incidence of parapneumonic pleural effusion among
patients with chronic respiratory disorders treated with inhaled
steroids. These findings may be associated with the higher use of
previous antibiotics and steroids, and/or with the fact that patients
with COPD seek clinical advice earlier. It has recently been shown
that patients with COPD and CAP exhibit a different inflamma-
tory response with lower levels of certain serum biomarkers; this
finding may also help to explain these clinical differences [10].
The most frequent causative organism of pneumonia in all
patient groups was S. pneumoniae. However, pneumococcal
bacteremia was less frequent in patients with COPD. It is
tempting to attribute this finding to the higher rates of
pneumococcal vaccine recorded. Other possible explanations are
the earlier time of consultation in patients with COPD or the fact
that the pneumococcal serotypes isolated in COPD may differ
from those found in other patients. Further information is needed
regarding the microbiological characteristics of pneumococcal
pneumonia in patients with COPD.
The association of P. aeruginosa and COPD is well known, but
information regarding risk factors for P. aeruginosa pneumonia
among the COPD population is scarce [12,16–18,24]. We found
that patients with oxygen therapy at home presented more P.
aeruginosa pneumonia, but the only independent risk factor for P.
aeruginosa pneumonia in patients with COPD was FEV1 value.
Table 5. Factors associated with mortality in patients with COPD and pneumonia: multivariate analysis.
Variable OR 95% confidence interval p value
.65 years old 1.374 0.454–4.157 0.573
Chronic oral steroids 2.454 0.816–7.380 0.110
Chronic renal disease 2.211 0.573–8.531 0.249
Dementia 1.887 0.439–8.113 0.394
Multilobar pneumonia 2.883 1.299–6.399 0.009
Bacteremia 0.529 0.160–1.756 0.298
Septic shock 2.574 0.886–7.476 0.082
Pseudomonas aeruginosa pneumonia 19.091 4.326–84.256 ,0.001
Inappropriate empirical treatment 2.334 0.711–7.657 0.162
Cardiac complications 2.594 0.824–8.172 0.103
High-risk PSI classes 10.316 1.691–62.946 0.011
Metabolic complications 1.349 0.243–7.500 0.732
Nosocomial infection 0.484 0.067–3.486 0.471
Pneumococcal vaccine 0.232 0.072–0.754 0.015
COPD, chronic obstructive pulmonary disease; OR: odds ratio; PSI, pneumonia severity index.
doi:10.1371/journal.pone.0105854.t005
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Previous studies have also reported that markers of respiratory
functional impairment are the most important factors related to P.
aeruginosa isolation in the setting of COPD exacerbation [25,26].
Identifying patients with COPD with a higher risk of P.
Table 6. Characteristics of patients with COPD who had Pseudomonas aeruginosa pneumonia and those patients with COPD with
pneumonia non-caused by P. aeruginosa.
Variable
Patients with P. aeruginosa pneumonia
[n = 33], n (%)
Patients without P. aeruginosa pneumonia




Age, median (IQR), years 74 (68.25–77) 74 (67–80) 0.108
.65 years old 27 (84.4) 758 (79.8) 0.524
Male sex 31 (93.9) 859 (90.4) 0.497
Current smoker 7 (21.2) 245 (26.0) 0.066
Ex-smoker 24 (72.7) 511 (54.1) 0.066
Alcohol abuse 6 (18.2) 189 (20.1) 0.499
Influenza vaccine (season) 22 (81.5) 605 (71.1) 0.240
Pneumococcal vaccine, 5 years 11 (44) 215 (26.3) 0.049
Comorbid conditions
Diabetes mellitus 9 (27.3) 207 (21.8) 0.455
Chronic heart disease 5 (15.2) 260 (27.4) 0.120
Neoplastic disease 4 (12.1) 108 (11.4) 0.894
Chronic renal disease 1 (3.0) 66 (6.9) 0.380
Chronic liver disease 5 (15.2) 58 (6.1) 0.037
Cerebrovascular disease 2 (6.1) 67 (7.1) 0.826
Cognitive deficit (dementia) 0 (0) 38 (4.0) 0.241
Statin use1 1 (5.6) 88 (26.9) 0.044
Chronic oral steroids 7 (21.9) 95 (10.0) 0.031
Pre-hospital antibiotics 6 (18.8) 175 (19.1) 0.958
Prior antibiotic treatment 10 (30.3) 217 (22.8) 0.342
Prior hospitalization2 4 (13.8) 87 (12.2) 0.802
Clinical features at presentation
Fever ($38.0uC) 7 (22.6) 430 (45.7) 0.011
Acute onset of disease 11 (33.3) 435 (45.9) 0.155
Cough 31 (93.9) 828 (87.3) 0.259
Expectoration 30 (90.9) 704 (74.3) 0.030
Purulent sputum 25 (83.3) 525 (63.0) 0.023
Dyspnea 29 (87.9) 736 (77.6) 0.163
Tachypnea ($30 breaths?min21) 14 (51.9) 415 (48.4) 0.726
Pleuritic chest pain 16 (48.5) 403 (42.5) 0.492
Impaired consciousness 4 (12.1) 131 (13.8) 0.781
Septic shock 4 (12.1) 63 (6.6) 0.219
Diarrhea, vomiting 2 (6.1) 83 (8.7) 0.590
Headache 5 (15.2) 91 (9.6) 0.290
Arthromyalgias 5 (15.2) 134 (14.1) 0.869
Laboratory and radiographic findings at presentation
Respiratory failure (PaO2/FiO2,300 or PaO2,
60 mmHg)
20 (76.9) 604 (76.2) 0.929
Multilobar pneumonia 9 (28.1) 246 (26.0) 0.074
Pleural effusion 3 (9.4) 131 (13.8) 0.471
Empyema 0 (0) 21 (2.2) 0.388
High-risk PSI classes3 21 (63.6) 699 (73.8) 0.193
COPD, chronic obstructive pulmonary disease; IQR, interquartile range; PSI, pneumonia severity index.
1Data available only for 345 patients. 2Data available for 740 patients. 3Patients were stratified into the following risk classes according to the PSI score: low risk (#90
points, classes I, II, and III) and high risk (.90 points, classes IV and V).
doi:10.1371/journal.pone.0105854.t006
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aeruginosa pneumonia seems mandatory, as we found that this
population frequently received inappropriate antibiotic treatment
(more than 40%), and have high early (15.2%) and late mortality
(39.4%). Lack of coverage against P. aeruginosa has been
associated with early mortality in patients with CAP [27].
Therefore, P. aeruginosa should be taken into consideration
when selecting an initial empirical antibiotic treatment in
hospitalized patients with CAP and severe COPD, especially in
those receiving oxygen therapy at home and those admitted in
ICU.
In agreement with previous reports [28–30], patients with
COPD more frequently had recurrent CAP, ischemic cardiac
complications, and prolonged length of hospital stay. However,
early and overall mortality rates were similar in patients with and
without COPD, as other authors have suggested [12,20]. Although
patients with COPD have poorer respiratory function, they are
admitted to hospital sooner and have lower rates of multilobar
pneumonia, empyema and bacteremia. This setting suggests a
more balanced inflammatory response. The rates of early
mortality are notably low in patients with COPD and come close
to achieving statistical significance compared with patients without
COPD.
We found that multilobar pneumonia, Pseudomonas aeruginosa
pneumonia, and high-risk PSI class were associated with overall
case-fatality rate in patients with COPD. These factors have been
reported in previous studies [12,14,17,27]. Recent studies have
documented an increased incidence of acute cardiac events in
patients with CAP and have associated these events with poor
outcomes [28,31]. In our study, patients with cardiac complica-
tions have higher mortality in the univariate analysis. Chronic oral
steroids alter immune host response and exert a decisive influence
on macrophage and granulocyte late function. As previously
suggested [32], recovery of lung homeostasis could be seriously
compromised by steroid administration at a late stage of infection.
Although it has been suggested that inhaled steroids produce an
excess risk of severe pneumonia in patients with COPD [33], the
data regarding their impact on mortality are contradictory [34–
36]. In our study, we did not find increases in early and overall
mortality among patients receiving oral or inhaled steroids.
We found polysaccharide pneumococcal vaccination to be an
independent protective factor against mortality in patients with
COPD. Only 26.8% of patients with COPD had previously
received pneumococcal vaccine, despite the fact that the US
Advisory Committee on Immunization Practices recommends this
practice for all patients with COPD [37]. Pneumococcal
vaccination is believed to decrease the rates of invasive disease
caused by S. pneumoniae [38–40]. Furthermore, previous reports
have also found that pneumococcal vaccination may improve
outcomes in patients with pneumonia [41,42], including patients
with chronic lung diseases [43]. These findings should convince
clinicians of the importance of improving compliance with existing
pneumococcal vaccination recommendations in patients with
COPD.
The strengths of this study are the large number of patients
included, its prospective design, and the comprehensive clinical
and microbiologic data gathered. In addition, all patients with
COPD included in the study had a spirometric confirmation of the
disease. However, there are some limitations that should be
acknowledged. Firstly, the study was conducted at a single center
and the sample size was relatively small for some subsets of
patients with COPD such as those who died. Secondly, some
factors related with COPD function such as functional depen-
dence, dyspnea score, walking test or BODE index were not
available for the study. These factors may have influenced COPD
mortality and/or risk for P. aeruginosa pneumonia. Finally, we
lack information regarding prior isolation of P. aeruginosa in
sputum in patients with COPD.
In conclusion, CAP in patients with and without COPD
presents distinct clinical features. Although S. pneumoniae is the
leading causative organism, Gram-negative bacilli and P.
aeruginosa should also be taken into account, especially in
patients with severe COPD receiving oxygen therapy at home.
Multilobar pneumonia, Pseudomonas aeruginosa pneumonia, and
high-risk PSI class were associated with overall case-fatality rate in
patients with COPD. Conversely, prior pneumococcal vaccine was
found to be protective, which should encourage physicians to
increase the use of this vaccine in the COPD population.
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